Center for Cognitive and Memory Disorders

KelleyBrendanAssociate Professor of Neurology and Psychiatry; Vice-Chair for Clinical Affairs

College of Medicine
Neurology, Memory and Cognitive Disorders Division
Department of Neurology, The Ohio State University

395 W. 12th Ave., 7th Floor
Columbus, Ohio 43210-1239

Research Interests: Mild cognitive impairment, Alzheimer’s disease, Lewy body dementia, vascular cognitive impairment, autoimmune encephalopathy/autoimmune dementia

Research Lab Goals: The division participates in multiple research endeavors and collaborations to identify new treatments for Alzheimer’s disease, mild cognitive impairment, Lewy body dementia and vascular cognitive impairment. In addition to clinical research, the Cognitive and Memory Disorders Program collaborates with researchers at Ohio State and at other institutions to further the scientific understanding of these diseases.

Research Techniques: Clinical trials, brain imaging including MRI, FDG-PET, amyloid-PET, tau-PET, cerebrospinal fluid analyses

Active Funding:

  • 2015- Principal Investigator, A 24-month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
  • 2015- Co-Investigator, Distinguishing Between Alzheimer’s Disease, Lewy Body Dementia and Parkinson’s Disease
  • 2014- Co-Investigator, Validity of the Electronic Self-Administered Gerocognitive Examination (ESAGE)
  • 2013- Co-Investigator, Alzheimer’s Disease Neuroimaging Initiative-2 (ADNI-2) ADC039 NIA
  • 2013- Key Personnel, Validation of Functional Polymorphisms in Existing Clinical Cohorts
  • 2013- Genomic studies on Dementia with Lewy Bodies. Mangurian Foundation (via Dr. Scharre, Neurology, OSUMC).
  • 2013- Co-Investigator, EVP-6124-026: A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
  • 2013- Co-Investigator, EVP-6124-024: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
  • 2013- Co-Investigator, 019-00: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (prodromal AD)
  • 2013- Co-Investigator, 012-02: A Aeamless Phase IIA/IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer’s Disease
  • 2013- Co-Investigator, 14861B: An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of LU AE58054 as an Adjunctive Treatment to Acetylcholinesterase Inhibitors in Patients with Mild-Moderate Alzheimer’s Disease
  • 2013- Co-Investigator, Cerebral Fluid (CSF) and Blood Repository (Buckeye Biospecimen Repository): Evaluating Biomarkers for Degenerative Brain Conditions
  • 2011-2013 Principle Investigator, Retrospective Study of Outpatients with Autoimmune Encephalopathy
  • 2010-2011 Group, Double-Blind, Multi-center Study Comparing the Effects of Rivastigmine Patch 15cm2 vs. Rivastigmine Patch 5cm2 on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer’s Type

PubMed articles

BS/Physics, The Ohio State University
BA/Russian Literature, The Ohio State University
MS/Physics, Cornell University
MD, The Ohio State University

Residency: Neurology Residency, Cleveland Clinic Foundation

Behavioral Neurology Fellowship, Mayo Clinic Rochester
Multiple Sclerosis/Neuroimmunology Fellowship, Mayo Clinic Rochester

My Clinical Bio

Share this Page